DiagnosTear Technologies Inc. develops innovative diagnostic solutions for eye diseases, including the CE-IVD approved TeaRx Dry Eye test. While the company shows strong liquidity with a current ratio of 6.02 and minimal debt (0.02), its financial health is concerning due to negative ROE (-117.9%) and ROA (-89.7%), indicating operational inefficiencies. The recent price increase of 11.11% may reflect market interest, but the low market cap of $13.69M suggests potential volatility and risk. Overall, while there are strengths in liquidity, the negative returns raise red flags for investors.
Loading financial metrics...
Company has $1.1M in cash but burned $714K last quarter. At this burn rate, only 1.6 quarters of runway remain without additional financing.
Company posted a loss of $-19.9M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $2.9M over the last year.
Fortress balance sheet: cash covers total debt 34×, providing significant financial flexibility.
Excellent liquidity with current ratio of 6.0x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Instruments & Supplies companies of a similar size
Based on 2025-Q3 (September 30, 2025)